News

Presentations and Publications

A Phase 1 trial of PRTH-101, a monoclonal antibody targeting discoidin domain receptor 1 (DDR1), alone or in combination with pembrolizumab, for the treatment of thymic malignancies | Poster | ITMIG 2025

A pivotal Phase 2 trial to compare PRTH-101, a monoclonal antibody targeting discoidin domain receptor 1 (DDR1), in combination with an immune checkpoint inhibitor (ICI) to ICI alone, for the treatment of recurrent or metastatic thymic epithelial carcinoma (TEC) | Poster | ITMIG 2025

View More Presentations and Publications

Recent Press Releases

October 2, 2025 | Incendia Therapeutics Presents Two Posters on its Lead Asset PRTH-101 in Thymic Cancers at the 15th International Thymic Malignancy Interest Group (ITMIG) Annual Meeting

December 11, 2024 | Incendia Therapeutics Appoints Renowned Biotechnology Investor and Entrepreneur Louis G. Lange, M.D., Ph.D., to Board of Directors

December 3, 2024 | Incendia Therapeutics Appoints Bradford Smith as Chief Financial Officer

PRTH-101, a Novel DDR1 Inhibitor

View More Press Releases

In the News

December 18, 2024 | Incendia Therapeutics President & CEO Wendye Robbins is featured in GBHNews’ new Women in Biotech series. Hear her perspective on leadership and empowering women in biotech.

October 31, 2023 | PathAI Announces Research Presentations at the Society for Immunotherapy of Cancer's 38th Annual Meeting

October 30, 2023 | Alpenglow Biosciences, Inc. Sponsors Dinner Lecture titled "Decoding Immune Exclusion and Tumor Evasion in the TME", featuring Dr. Laura Dillon, PhD of Incendia Therapeutics

View More News